Endocrine Abstracts

Background: A reduced injection force potentially makes it easier for patients to administer their injected medication.Objective and Hypotheses: This report compares dose force, dose accuracy and dose precision of two growth hormone injection devices: Norditropin® NordiFlex® (NF) (Novo Nordisk A/S, Denmark) and Genotropin® GoQuick® (GQ) (Pfizer Inc, NY, USA).Methods: M...

Background: Clinical manifestations, metabolic risk factors and diabetes risk may differ in ethnical subgroups of women with PCOS.Material and methods: A total of 1010 premenopausal women were referred with the diagnoses hirsutism or PCOS during 1997–2008. The patients underwent clinical evaluation, hormone analyses and transvaginal ultrasound (US). Oral glucose tolerance tests (OGTT) (n=500) and ACTH tests (n=434) were performed in a ...

Background: Testosterone replacement therapy in severe hypogonadism is indicated, however, the treatment of late onset hypogonadism (LOH) is debated, especially what the diagnostic criteria should be. In LOH bio-available testosterone probably gives a more accurate index of gonadal status as a diagnostic criterion as it takes SHBG into consideration. SHBG is known to increase with ageing, however, SHBG is also negatively influenced by insulin and visceral adiposity.<p clas...

Objective: PCOS patients are often characterized by insulin resistance, abdominal obesity, and low-grade inflammation. Insulin sensitizing treatment reduces the inflammatory state, but the effect on serum levels of chemokines such as migration inhibitor factor (MIF), monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1α have not previously been evaluated in PCOS.Research design and methods: Plasma chemokine levels (M...

Introduction: Pituitary conditions are rare and diagnosis may be slow because symptoms are ambiguous. The treatment may be a combination of surgery, radiotherapy and medication so patients see many healthcare professionals (HCPs). This survey sought to assess patient satisfaction with the information and support they receive from GPs, endocrinologists, neurosurgeons, radiotherapists, specialist nurses, and other agencies (e.g. the pituitary foundation).M...

Objective: To describe body-composition, lipid profile, and health-related quality of life (HRQL) in patients with traumatic brain injury (TBI) in relation to the development of posttraumatic hypopituitarism.Design: Cross-sectional with a nested prospective sub-study.Patients: The cross-sectional cohort included 104 hospitalized patients with TBI (26F/78M; age: median 41 years (range 18–64); BMI: 25 kg/m2 (17–3...

Objective: Untreated overt hyperthyroidism is known to predispose the patient to cardiovascular diseases, while predisposition in subclinical hyperthyroidism has been debated. The1 cut-off point of TSH for initiating treatment in subclinical hyperthyroidism is still undefined.Method: A community-based prospective study including non-hospitalised participants, aged 51 to 91 years, living in Copenhagen, Denmark were examined between September 1998 and Janu...

Background: Plasma normetanephrine levels are an annual screening tool for detecting paragangliomas in SDHB mutation carriers. Sensitivity is increased when patients are fasting and recumbent prior to phlebotomy, to allow use of age-adjusted reference ranges rather than the 1180 pmol/l upper limit for ambulatory patients of any age. We present our clinic’s results of samples taken after 30 minutes of recumbency to determine if applying age-adjusted ranges...

Introduction: We questioned the justification of general recommendations for assessment of hypopituitarism in patients with traumatic brain injury (TBI), and aimed to describe the prevalence of hypopituitarism in a national TBI population of patients admitted to a Danish hospital in 2008, as compared to healthy controls.Patients and methods: We included 463 patients (18–65 years) hospitalized ≥24 h, with more than subtle TBI as indicated by lo...

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...